Summary of CLPT Q3 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $8.9 million for Q3 2025, up 9% from $8.1 million in Q3 2024.

Revenue Breakdown:

Biologics and Drug Delivery: $4.4 million (consistent year-over-year).

Neurosurgery Navigation Therapy: $3.4 million (20% growth).

Capital Equipment and Software: $1 million (25% growth).

Gross Margin: 63%, up from 60% in Q3 2024.

R&D Expenses: $3.5 million, a 4% increase.

Sales and Marketing Expenses: $3.8 million, an 8% increase.

General and Administrative Expenses: $3.6 million, a 14% increase.

Cash Position: $38.2 million as of September 30, 2025, up from $20.1 million at the end of 2024.

2Strategic Updates and Business Highlights

ClearPoint Neuro is undergoing a strategic transformation with two main phases:

Fast Forward: Launching new products in existing markets worth over $1 billion.

Essential Everywhere: Building a new $10 billion market for neuro drug delivery.

Announced a merger with IRRAS, expected to close in Q4 2025, which will enhance ClearPoint's market position in neurocritical care.

The IRRAflow catheter will provide access to a $500 million market for intracranial fluid management.

ClearPoint aims to integrate IRRAS swiftly, leveraging a combined commercial team of over 40 professionals.

3Forward Guidance and Outlook

2025 Revenue Forecast: Narrowed to $36 million - $38 million.

2026 Revenue Guidance for Merged Entity: Expected to be between $54 million - $60 million.

Anticipated growth in biologics and drug delivery, with expectations of returning to double-digit growth in Q4 2025.

4Bad News, Challenges, or Points of Concern

Revenue growth was lower than previous quarters due to the transition to a new CRO facility, which temporarily diverted resources.

Increased operational costs in R&D, sales, and general administration due to expansion efforts.

The company faces competitive pressures in the neurocritical care market, which has seen little innovation historically.

5Notable Q&A Insights

Market Size and Penetration: The neurocritical care market is estimated at $500 million, with 400,000 procedures annually. ClearPoint aims to penetrate this market with innovative solutions.

Gross Margin Outlook: IRRAS has a gross margin in the mid-50s, while ClearPoint's is at 63%. The merger is expected to enhance overall margins as operations scale.

Cash Burn Profile: Expected to be in the mid-to-high single digits in the first year post-merger due to integration costs, but anticipated to decrease over time.

New CRO Facility: The facility allows for larger and higher-value studies, with potential project sizes of $5 million to $10 million, significantly larger than previous capabilities. This earnings call reflects a pivotal moment for ClearPoint Neuro as it positions itself for growth through strategic acquisitions and expansion into new markets while navigating operational challenges and competitive dynamics.